FDA approves new therapy for PKU

by Lisa Spellman, UNMC public relations | June 20, 2018

Image with caption: William Rizzo, M.D.

William Rizzo, M.D.

On May 25, the U.S. Food and Drug Administration approved Palynziq (pegvaliase-pqpz), a new enzyme substitution therapy for adults with a rare and serious genetic disease known as phenylketonuria (PKU).

picture disc.
Jennifer Harney, M.D.
That's good news for Jennifer Harney, M.D., who was diagnosed at birth with PKU and participated in a clinical trial for three years headed by William Rizzo, M.D., professor of pediatrics at UNMC's Munroe-Meyer Institute.

"The therapy has given me significantly improved energy and mental activity," Dr. Harney said.

"I've been able to include more dietary protein in what I eat and don't need to restrict my meals so heavily (there's several times in the past I would just skip meals if I was unable to eat what was provided) and don't need to spend hours ordering, prepping, and storing specially created low-phenylalanine foods. That's been a huge relief with my already busy schedule," she said.

All babies in the U.S. are screened at birth for PKU due to its severe consequences on the brain. Patients with PKU are born with the inability to break down phenylalanine (Phe), an amino acid present in protein-containing foods and high-intensity sweeteners used in a variety of foods and beverages.

Unmanaged, PKU can lead to neurological damage and intellectual impairment. Because the diagnosis requires strict adherence to a protein-free diet, Dr. Harney has had to avoid meat, fish, eggs, nuts and dairy her entire life.

The safety and effectiveness of the Palynziq enzyme substitution therapy was studied in two clinical trials in adult patients with PKU. The first trial was a randomized, open-label trial in patients treated with increasing doses of Palynziq administered as an injection up to a target dose of either 20 mg or 40 mg once daily.

The second trial was an eight-week, placebo-controlled, randomized withdrawal trial in patients who were previously treated with Palynziq. Patients treated with Palynziq achieved statistically significant reductions in blood phenylalanine concentrations from their pre-treatment baseline blood Phe concentrations.

PKU affects about 1 in 10,000 to 15,000 people in the United States. This new treatment will change lives, said Dr. Rizzo.

"What this enzyme therapy does is allow PKU patients, who have been on lifelong protein restriction, to normalize their diet," he said.

Dr. Rizzo said he will now be able to prescribe the FDA-approved enzyme therapy for those patients who want it. He also continues to take part in an ongoing clinical trial for patients who need an even higher dose of the therapy than what was just approved by the FDA.

The FDA granted approval of Palynziq to BioMarin Pharmaceutical Inc.

Comments

Fill out the following and your comment will post once it has been approved.

Name (Required)

Email (Required)

Thank you, your comment will appear below once it has been approved.

Nicole Phillips
July 06, 2018 at 12:14 PM

This is so awesome! I can't wait to try this out! I have also struggled my entire life with PKU!!

Patty
June 20, 2018 at 6:53 AM

Great news Dr. Rizzo!